US pharma’s Chinese biotech deals face uncertainty under Treasury proposal
Proposed US limits on investments in Chinese biotechnology could make American drugmakers less competitive against foreign rivals and disrupt the complex partnerships that have made China an important source of new...To view the full article, register now.
Already a subscriber? Click here to view full article